Research And Development Expense

Name: Tango Therapeutics Research And Development Expense by Business Segments
Creator: OpenCapital
License: https://www.opencapital.sh/terms

Tango Therapeutics·Business Segments·8 segments·Rolls up to R&D

Breakdown

Segment	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Personnel-Related Expenses-RD	$13.85M	$12.83M	$12.38M	$12.41M	$12.93M
Vopimetostat Direct Program Expenses-RD	—	—	$6.07M	$9.41M	$9.33M
Facilities And Other Related Expenses-RD	$5.47M	$5.43M	$4.9M	$4.67M	$4.34M
TNG456Direct Program Expenses-RD	$1.32M	$1.65M	$2M	$1.59M	$2.06M
TNG260Direct Program Expenses-RD	$1.73M	$1.81M	$1.66M	$1.08M	$2.01M
Discovery Direct Program Expenses-RD	$4.68M	$2.71M	$1.5M	$1.28M	$1.87M
TNG908Direct Program Expenses-RD	$1.71M	$1.24M	$1.23M	$845K	$581K
TNG961Direct Program Expenses-RD	$2.22M	$1.57M	$1.07M	$813K	$408K
Total	$36.44M	$32.81M	$30.82M	$32.1M	$33.53M

Segments

Discovery Direct Program Expenses-RDView metric

Facilities And Other Related Expenses-RDView metric

Personnel-Related Expenses-RDView metric

TNG260Direct Program Expenses-RDView metric

TNG456Direct Program Expenses-RDView metric

TNG908Direct Program Expenses-RDView metric

TNG961Direct Program Expenses-RDView metric

Vopimetostat Direct Program Expenses-RDView metric